BIOINVEST BREAKING NEWS – Celldex (CLDX) — After the close, CLDX announced that treatment with barvolvolimab (“barzo”) did not work in the Phase IIb trial in prurigo nodularis (PN). While barzo significantly and safely depleted mast cells, PN is complex immune-mediated neurological condition that is not obviously driven by primarily mast cells – which urticaria is. (…more)
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.